The arrival of Retatrutide in the nation is creating significant excitement within the obesity community. This groundbreaking dual agonist – targeting both GLP-1 and GIP – offers a significantly new approach to tackling obesity . Until recently, options have been constrained for many, and Retatrutide represents a promising possibility for patie